Ajona Daniel, Cragg Mark S, Pio Ruben
Laboratory of Translational Oncology, Program in Solid Tumors, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, Universidad de Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain.
Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK.
Semin Immunol. 2025 Mar;77:101921. doi: 10.1016/j.smim.2024.101921. Epub 2024 Dec 18.
The complement system, a key component of innate immunity, is involved in seemingly contradictory aspects of tumor progression and cancer therapy. It can act as an immune effector against cancer and modulate the antitumor activity of certain therapeutic antibodies, but it can also contribute to a tumor-promoting microenvironment. Understanding this dual role should lead to the development of better therapeutic tools, strategies for cancer treatment and biomarkers for the clinical management of cancer patients. Here, we review recent advances in the understanding of the role of complement in cancer, focusing on how these findings are being translated into the clinic. We highlight the activity of therapeutic agents that modulate the complement system, as well as combination therapies that integrate complement modulation with existing therapies. We conclude that the role of complement activation in cancer is a rapidly evolving field with the potential to translate findings into new therapeutic strategies and clinically useful biomarkers.
补体系统是固有免疫的关键组成部分，参与肿瘤进展和癌症治疗中看似矛盾的多个方面。它可以作为抗癌免疫效应器并调节某些治疗性抗体的抗肿瘤活性，但也会促成促肿瘤微环境。了解这种双重作用应能推动更好的治疗工具、癌症治疗策略以及癌症患者临床管理生物标志物的开发。在此，我们综述了补体在癌症中作用的最新研究进展，重点关注这些研究结果如何转化到临床应用中。我们强调了调节补体系统的治疗药物的活性，以及将补体调节与现有疗法相结合的联合疗法。我们得出结论，补体激活在癌症中的作用是一个快速发展的领域，有可能将研究结果转化为新的治疗策略和具有临床应用价值的生物标志物。
